Posted by Hugh on June 6, 2019, at 12:27:45
In reply to Re: SAGE-217 » Hugh, posted by sigismund on June 5, 2019, at 23:52:08
Sage-217 works on a different part of the GABA-A receptor than benzodiazepines. And taking it for 14 days seems to get the receptors to function better long-term, for many, and perhaps even permanently, for some. They've only followed up for 30 days after the clinical trials, so only time will tell how long its effects last.
The following is from Sage's website:
The GABA system is the major inhibitory signaling pathway of the central nervous system (CNS), and contributes significantly to regulating CNS function. SAGE-217 is a novel, highly potent and selective, next generation GABAA receptor positive allosteric modulator that is being developed as a once-daily, oral therapy for the treatment of various CNS disorders.
Complete article:
Here's a Q&A session transcript from Sage Therapeutics:
https://investor.sagerx.com/static-files/e269a056-a358-4120-8302-5b6ce278ba19
poster:Hugh
thread:1104754
URL: http://www.dr-bob.org/babble/20190513/msgs/1104767.html